Sequential study of the bone marrow granulocytic progenitor cells (CFC *) in children treated by chemotherapy for non-hodgkin malignant lymphomas.
We have studied the time course changes in committed granulocytic progenitor cells (CFC) in 54 pediatric patients treated by chemotherapy for a malignant non-Hodgkin lymphoma. This study has revealed the following points: 1) In the absence of patent bone marrow invasion, the bone marrow CFC concentration is, before treatment, less than normal; 2) Bone marrow invasion coincides with a large decline in bone marrow CFC concentration; 3) The aplasia induced by the initial chemotherapy is mediated by a quasi-complete destruction of CFC; 4) After regeneration from the initial therapeutic aplastic state the CFC exhibited a quite variable behavior from one patient to another. This phenomenon is probably linked to the variable recuperation time for each patient; 5) Following the conclusion of treatment, the patients, although having a normal peripheral leukocyte count, appeared to maintain a major aftereffect characterized by a clear and prolonged reduction in the concentration and total number of CFC.
D000293:Adolescent; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000494:pharmacology / Q000627:therapeutic use; D004317:Doxorubicin / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006098:Granulocytes / Q000473:pathology*; D006412:Hematopoietic Stem Cells / Q000473:pathology*; D006801:Humans; D007958:Leukocyte Count; D008223:Lymphoma / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D011241:Prednisone / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D014750:Vincristine / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone